Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites
Key Highlights
- ➤NYU Langone Health joins Aclarion’s (ACON) CLARITY trial network as the eleventh enrolling site
- ➤CLARITY trial will enroll 300 patients undergoing fusion or TDR surgery for discogenic low back pain
- ➤Trial’s primary endpoint measures 12-month back-pain change using the 100mm VAS Back
- ➤Nociscan reports a 97% surgical success rate when all positive discs are treated
Expert Statements
Jeffrey A. Goldstein, Director, Spine Surgery Fellowship Program and Clinical Professor of Orthopedic Surgery and Neurosurgery, NYU Grossman School of Medicine, NYU Langone Health
“Every patient who comes to me with chronic low back pain has a story — potentially years of trying to find answers, manage symptoms, and get their life back. As surgeons, we owe it to them to use appropriate tools to understand what is truly driving their pain before we recommend treatment.”
Ryan Bond, Chief Strategy Officer of Aclarion
“NYU Langone Health is one of the most respected academic medical centers in the country, and Dr. Goldstein is widely recognized for his expertise in spine surgery and his commitment to innovation and research. Their addition to the CLARITY network reflects the growing interest among leading institutions in the clinical value Nociscan can bring to surgical decision-making for chronic low back pain.”
* NYU Langone Health is a nationally recognized academic medical center with deep expertise in spine surgery, minimally invasive procedures, robotic spine surgery, and clinical research * CLARITY is a prospective, randomized clinical trial designed to demonstrate Nociscan’s ability to improve surgical outcomes for chronic low back pain * Nociscan(® )aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced NYU Langone Health as a new clinical site in its CLARITY (Chronic Low bAck pain Randomized Independent Trial studY) trial. The groundbreaking CLARITY study is designed to demonstrate Nociscan's clinical and economic value in spine surgery.
Get started
Create a free account to read the full story.